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Sex Med 2Introduction: Premature ejaculation (PE) is one of the commonest sexual dysfunctions in men. Because the
deﬁnition of and guidelines for the management of PE have been revised in recent years, our understanding of PE
has changed.
Aim: To investigate the clinical practice patterns of sexual medicine specialists regarding the diagnosis and
treatment of PE.
Methods: Attendees of the 17th Annual Congress of the European Society of Sexual Medicine, held in February
2015 in Copenhagen, Denmark, were asked to participate in a survey during the congress.
Main Outcome Measures: A 23-item, self-reported, closed-question questionnaire was distributed. Sociodemo-
graphic data, professional background, and personal practice patterns of the attendees were assessed in relation to PE.
Results: In total, 217 physicians (median age ¼ 47 years, range ¼ 22e74) completed the survey. Most
responders (79.3%) considered PE an important sexual dysfunction that should be treated. Almost half the
participants stated there is insufﬁcient information about PE for patients and physicians (46.1% and 45.2%,
respectively). When asked about the main goal of treating PE, two thirds responded that main goal is to improve
patients’ sexual function and 35.9% responded that the main goal was to improve partners’ satisfaction.
Conclusion: These ﬁndings conﬁrmed that there are many differences among sex health experts in their
understanding of PE. Educational activities are crucial in implementing the new guidelines on PE.
Sex Med 2016;4:e209ee216. Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the Inter-
national Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Sexual DysfunctionINTRODUCTION
Premature ejaculation (PE) is one of the commonest sexual
dysfunctions in men, with prevalence rates estimated at 3% to
30%.1e4 Previous surveys have found that most men with PEnuary 23, 2016. Accepted May 22, 2016.
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016;4:e209ee216do not seek treatment; therefore, there is a large discrepancy
in the estimated prevalence of PE in the population vs those
who are referred to clinics.5,6 This problem can present since
the ﬁrst sexual experience and can be deﬁned as lifelong
(primary) PE or it can be acquired (secondary) later in life.7
These two types of PE often cause distress for men and
their partners.8
Several professional organizations have drafted deﬁnitions of
PE because of the difﬁculty of using objective measurements for
this problem.9 The International Society for Sexual Medicine
recently developed a uniﬁed deﬁnition for lifelong and acquired
PE: “PE is a male sexual dysfunction characterized by:
 ejaculation that always or nearly always occurs prior to or
within about 1 minute of vaginal penetration from the ﬁrst
sexual experience (lifelong PE), OR a clinically signiﬁcant
reduction in latency time, often to about 3 minutes or less
(acquired premature ejaculation);e209
Table 1. Characteristics of sexual medicine experts
n %
Professional background
Urologist 183 84.3
Psychiatrist 20 9.2
General practitioner 14 6.5
Sex
Men 148 68.2
Women 69 31.8
Location of practice
Europe 171 78.9
Middle East 37 17
Asia 9 4.1
Duration of practice in sexual medicine
<5 y 52 23.9
5e10 y 54 24.9
>10 y 111 52.1
Type of practice
Private 63 29
Academic hospital 74 34
Public hospital 36 16.6
Private practice and public hospital 38 17.5
Other 6 2.9
e210 Shechter et al the inability to delay ejaculation on all or nearly all vaginal
penetrations; and
 negative personal consequences, such as distress, bother, frus-
tration, and/or the avoidance of sexual intimacy.”10
The American Psychiatric Association also published a deﬁ-
nition of PE in the Diagnostic and Statistical Manual for Mental
Disorders, Fifth Edition (DSM-5), where PE is deﬁned as “A
persistent or recurrent pattern of ejaculation occurring during
partnered sexual activity within approximately 1 minute
following vaginal penetration and before the individual wishes it.
This must have been present for at least 6 months and must be
experienced on almost all or all (approximately 75%e100%)
occasions of sexual activity (in identiﬁed situational contexts or,
if generalized, in all contexts). In addition, it causes clinically
signiﬁcant distress in the individual and it is not better explained
by a nonsexual mental disorder or as a consequence of severe
relationship distress or other signiﬁcant stressors and is not
attributable to the effects of a substance/medication or another
medical condition.”11
A recent survey conducted by Shindel et al12 evaluated the
practice pattern among American urologists in the management
of PE. The results demonstrated that most urologists who
responded to the survey followed the American Urological
Association 2004 guidelines on the management of PE.13
Because deﬁnitions of and guidelines for PE have undergone
some revisions in recent years, the present survey investigated
clinical practice patterns of specialists working in sexual medicine
regarding the diagnosis and treatment of PE. Based on the re-
sponses, our intention was to develop an ofﬁcial statement of the
European Society for Sexual Medicine on the management of PE.METHODS
Attendees of the 17th Annual Congress of the European
Society for Sexual Medicine, held in February 2015 in Copen-
hagen, Denmark, were invited to participate anonymously in a
self-administered questionnaire comprising 23 closed questions
(Appendix 1). The survey included a short introduction, which
requested the participants to complete the questionnaire covering
the criteria for diagnosis of PE and their current clinical practice
patterns related to PE treatment.MAIN OUTCOME MEASURES
The survey consisted of two sections: (i) ﬁve items assessing
sociodemographic data and information addressing the profes-
sional background of the respondents and (ii) 18 items assessing
information about participants’ current clinical practice patterns
in the diagnosis and treatment of PE (Appendix 1).Statistical Analyses
All statistical analyses were performed using SPSS 22 (IBM
Corp, Armonk, NY, USA).RESULTS
Overall, 217 sexual medicine experts participated in the sur-
vey. The median age was 47 years (age range ¼ 22 to 74 years)
and 68.2% were men. Urologists were in the majority (84.3%),
followed by psychiatrists (9.2%) and family physicians (6.5%).
Of the participants, 52.1% had practiced sexual medicine for
more than 10 years, 24.9% had practiced for 5 to 10 years, and
23.5% had practiced for less than 5 years in their discipline
(Table 1).
Most responders (79.3%) considered PE an important sexual
dysfunction that should be treated. Of the participants, 11.5%
recorded that PE should be treated only if the patient is really
bothered by it, whereas 9.2% did not believe that PE should be
treated. Almost half the participants stated that the information
available about PE was insufﬁcient for patients and physicians
(45.6% and 45.2%, respectively).
Forty-nine percent of participants reported that they
frequently encountered men with PE (more than 10 new cases
per month) and another 9.2% reported such encounters at least
occasionally. Of the participants, 51.1% responded that the
pivotal measurement for a PE diagnosis is the measured or
estimated intravaginal ejaculation latency time, followed by
perceived control over ejaculation (24.5%) and personal distress
related to ejaculation (24.4%). Of the participants, 62.2%
responded that it is “very important” to involve the partner in the
treatment decision and 30.8% responded that it is “quite
important” to include the partner.
When asked about the main goal of treating PE, 66.4%
responded that the main goal was to improve the patient’s sexualSex Med 2016;4:e209ee216
Attitudes Toward Premature Ejaculation e211satisfaction, 35.5% responded that the main goal was to improve
the partner’s satisfaction, and the rest responded that the main
goal was to improve control over ejaculation. Most participants
(66.4%) recommended combined treatment of pharmacotherapy
and psychotherapy for PE, whereas 17.1% recommended psy-
chotherapy (performed by sexologist) only and the rest recom-
mended pharmacotherapy only. The most commonly prescribed
drug for lifelong PE was an on-demand selective serotonin re-
uptake inhibitor (SSRI; 44.2%), whereas 26.3% and 10.1%
prescribed daily SSRI and topical treatment, respectively. The
vast majority of participants (98.2%) noted that they informed
their patients properly before prescribing an off-label antide-
pressant for the treatment of PE. Of the participants, 51.6%
considered topical treatments an effective therapeutic option for
PE and 18.9% stated that they also prescribed tramadol. Most
participants scheduled a follow-up visit 4 weeks after the pre-
scription of a treatment for PE (56.2%), whereas 20.3%
scheduled it within 2 months and the rest scheduled a visit after a
longer period.
Participants also were asked about their approach to patients
with acquired PE; 16.4%, 18.8%, and 47.2% reported that they
preferred topical treatments, daily SSRI, and on-demand SSRI,
respectively. Of note, 17.6% stated that they referred the patient
to a sexologist.
DISCUSSION
Although PE was initially described more than a century
ago,14 its deﬁnition, epidemiology, and management continue
to be a matter of discussion among physicians.15 Our ﬁndings
conﬁrmed that there are many differences among sexual health
experts in their understanding of PE. Despite the numerous
studies and guidelines published within the past two decades
and recently accumulated data on the pathophysiology and
treatment modalities of PE,16 9% of participants reported that
patients with PE do not need to be treated. We believe that
this underestimation of PE is because of the lack of proper
education in sexual medicine during medical training. A recent
survey of European urology residents showed that they could
not follow the recommendations of current treatment guide-
lines, although almost 15% of patients presenting to clinics
complain of PE.17
Diagnosis of PE has evolved owing to the establishment of
“normal” and “premature” ejaculation latencies.18e20 After the
pivotal studies of Waldinger et al20,21 that demonstrated that
most patients with lifelong PE ejaculate within 1 minute of
penetration, the evidence-based PE deﬁnitions included the
“short ejaculation time” criterion.9,10 Recently, the DSM-5 also
stated the 1-minute ejaculation time criterion for the diagnosis of
PE.11 Moreover, the DSM-5 classiﬁed the severity of PE as mild,
moderate, or severe according to ejaculation time.11 However,
ejaculation time is not the only criterion for the diagnosis of PE,
because several well-designed observational studies have
demonstrated that distress, lack of ejaculatory control, andSex Med 2016;4:e209ee216interpersonal difﬁculty also are bothersome for patients with
PE.22,23 Owing to these different aspects of the problem, par-
ticipants of this survey indicated that estimated intravaginal
ejaculation latency time (51.1%), perceived control over ejacu-
lation (24.5%), and personal distress (24.4%) were the pivotal
measurements for PE.
Recent guidelines have recommended topical anesthetic
creams or daily or on-demand SSRIs as ﬁrst-line pharmaco-
therapy for PE.16 However, psychotherapy (alone or in combi-
nation with pharmacotherapy) also can be beneﬁcial. Most
participants in this survey noted that they preferred the com-
bination of pharmacotherapy and psychotherapy for PE, whereas
17% recommended psychotherapy only, despite inconsistent
evidence supporting its long-term efﬁcacy.24 Although we
believe that sexual counseling and other psychological in-
terventions should not be completely abandoned, educational
courses on modern PE treatment could be of beneﬁt for
increasing the awareness of physicians of pharmacologic treat-
ment options.
In a similar study designed to ascertain the practice patterns of
207 U.S. urologists in the management of PE, Shindel et al12
reported that 73% of respondents saw fewer than one patient
with PE per week. However, half the physicians who participated
in our survey reported that they frequently encountered men
with PE (more than 10 new cases per month). This discrepancy
could be explained by the different characteristics of the partic-
ipants, because in the present study the survey was administrated
to attendees of a sexual medicine congress, whereas Shindel
et al12 randomly generated a mailing list of practicing urologists
from the American Urological Association member directory. In
contrast, the most commonly preferred drug in the present study
was on-demand SSRI (44%), which is in accordance with the
ﬁndings of Shindel et al.12
Dapoxetine, which is a rapidly acting SSRI with a short half-
life, is the ﬁrst approved oral medication for the treatment of PE
in many countries.16 Several well-controlled studies have
demonstrated the efﬁcacy of dapoxetine 30 or 60 mg when taken
orally 1 to 2 hours before intercourse. These studies reported
intravaginal ejaculation latency time increases of 2.5- to 3.0-
fold.25e27 However, it must be noted that 20% of patients with
PE who were prescribed on-demand dapoxetine did not start the
medication because of fear of using a new drug or because of the
cost of the treatment.28 Moreover, one study found that 90% of
patients with PE who initiated dapoxetine therapy discontinued
the treatment within 1 year owing to an efﬁcacy below expec-
tations (24.4%), cost (22.1%), adverse effects (19.8%), and loss
of interest in sex (19.8%).28 We believe that physicians must be
aware of these high discontinuation rates when prescribing
dapoxetine to patients with PE.29 Further studies must be
conducted to determine the true effectiveness and adverse effects
of the different treatments of PE and for the possibility of
educational activities to change the treatment approaches of
medical specialists.
e212 Shechter et alOur study is not without limitations. We limited the number
of questions in the survey after considering that expanding the
content of our questionnaire would signiﬁcantly decrease the
overall response rate, because congress attendees usually have a
busy agenda and might not be willing to complete a question-
naire that consisted of several pages. Moreover, comparison of
the approaches of physicians with different professional back-
grounds and different experience levels would provide more in-
formation about the variations in PE management. However, the
number of participants was not homogenously distributed when
we stratiﬁed them and there was not enough power to have valid
statistical outcomes. We believe that future studies with more
participants could elucidate this issue.CONCLUSIONS
Our ﬁndings conﬁrmed that there are many differences among
sex health experts in their understanding of PE and their treat-
ment approaches. Educational activities might be necessary to
increase their awareness and knowledge about the recent de-
velopments and evolved guidelines for the treatment of PE.Corresponding Author: Ege Can Serefoglu, MD, FECSM,
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Appendix 1. Questionnaire
Section 1: demographic data
Please specify your
Age (y):
Sex:, man , woman
Country of origin:
Country of practice:
Section 2: professional background
1. Please specify your occupation
Physician 1 ,
Psychologist 2 ,
Sexual therapist 3 ,
Physical therapist 4 ,
Nurse (RN) 5 ,
Preclinical researcher 6 ,
Other; please specify
2. If you are a physician, please specify your specialty
Urologist 1 ,
Gynecologist 2 ,
Psychiatrist 3 ,
Endocrinologist 4 ,
Cardiologist 5 ,
General practitioner 6 ,
Other; please specify
3. For how long have you been practicing sexual medicine?
<5 y 1 ,
5e10 y 2 ,
>10 y 3 ,
4. Do you practice in a private clinic or in the public health care system?
Academic hospital 1 ,
Private clinic and private practice 2 ,
Public health care system 3 ,
Private and public health care systems 4 ,
Other; please specify
5. How many new patients with premature ejaculation do you encounter in a month (on average)?
<10 1 ,
10e20 2 ,
>20 3 ,
6. Do you consider premature ejaculation an important sexual dysfunction that deserves to be treated?
Yes 1 ,
No 2 ,
Only if the patient is really bothered by the condition 3 ,
7. How do you consider the available patient information on premature ejaculation?
Sufﬁcient; there is no necessity for further information 1 ,
Quite sufﬁcient; only some information is needed 2 ,
Largely insufﬁcient; there is a substantial lack of information 3 ,
8. How do you consider the physician information on premature ejaculation?
Sufﬁcient; there is no necessity for further information 1 ,
Quite sufﬁcient; only some information is needed 2 ,
Largely insufﬁcient; there is a substantial lack of information 3 ,
9. What do you think is the pivotal measurement for premature ejaculation?
Measured intravaginal ejaculation latency time 1 ,
Estimated intravaginal ejaculation latency time 2 ,
Personal distress 3 ,
Perceived control over ejaculation 4 ,
(continued)
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Appendix 1. Continued
Satisfaction with sexual intercourse 5 ,
Partner’s satisfaction or distress 6 ,
10. How important do you consider the partner’s involvement in the treatment decision?
Not very important 1 ,
Quite important 2 ,
Very important 3 ,
11. What’s your main goal on treating premature ejaculation? (you can mark several answers)
Improve intravaginal ejaculation latency time 1 ,
Improve control over ejaculation 2 ,
Improve patient sexual satisfaction 3 ,
Improve partner’s sexual satisfaction 4 ,
12. According to you, what is the main treatment for premature ejaculation to achieve a lifelong satisfactory result?
Pharmacologic treatment 1 ,
Sexological treatment (psychotherapy) 2 ,
Pharmacologic therapy plus psychotherapy 3 ,
13. Do you consider topical treatment an effective treatment option for premature ejaculation?
Yes 1 ,
No 2 ,
14. What is your usual approach after you have diagnosed lifelong premature ejaculation in a patient?
I prescribe a topical treatment 1 ,
I prescribe a daily dose of an antidepressant selective serotonin reuptake inhibitor 2 ,
I prescribe an on-demand selective serotonin reuptake inhibitor (dapoxetine) 3 ,
I refer him to a sexologist 4 ,
Other; please specify 5 ,
15. What is your approach for a patient diagnosed with acquired premature ejaculation?
I prescribe a topical treatment 1 ,
I prescribe a daily dose of an antidepressant selective serotonin reuptake inhibitor 2 ,
I prescribe an on-demand selective serotonin reuptake inhibitor (dapoxetine) 3 ,
I refer him to a sexologist 4 ,
Other; please specify 5 ,
16. When you prescribe an off-label antidepressant selective serotonin reuptake inhibitor for the treatment of premature
ejaculation, do you inform your patients that the prescription is off label?
Yes 1 ,
No 2 ,
Do not prescribe 3 ,
17. Do you prescribe dapoxetine (Priligy) for the treatment of premature ejaculation?
Yes 1 ,
No 2 ,
18. If yes, to how many new patients do you prescribe dapoxetine (Priligy) in a month (on average)?
<10 1 ,
10e20 2 ,
>20 3 ,
19. Do you prescribe tramadol for the treatment of premature ejaculation?
Yes 1 ,
No 2 ,
20. Do you prescribe other pharmacologic treatments for premature ejaculation?
Yes 1 ,
If yes, please specify
No 2 ,
21. Do you believe that sexual therapy (psychotherapy) is applicable to a patient who has no partner?
Yes 1 ,
No 2 ,
(continued)
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Appendix 1. Continued
22. Do you always schedule follow-up visits with your patients after prescription of a treatment for premature ejaculation?
Yes 1 ,
No 2 ,
23. If yes, when do you schedule the follow-up?
After 2 wk 1 ,
After 4 wk 2 ,
After 8 wk 3 ,
After >10 wk 4 ,
Sex Med 2016;4:e209ee216
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